Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Treatment of the Malignant Carcinoid Syndrome
1986656 citationsLarry K. Kvols, Charles G. Moertel et al.profile →
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
1991610 citationsCharles G. Moertel, Larry K. Kvols et al.profile →
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
2010519 citationsJonathan Strosberg, Aejaz Nasir et al.profile →
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009487 citationsJames C. Yao, Catherine Lombard‐Bohas et al.Journal of Clinical Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Larry K. Kvols
Since
Specialization
Citations
This map shows the geographic impact of Larry K. Kvols's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry K. Kvols with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry K. Kvols more than expected).
This network shows the impact of papers produced by Larry K. Kvols. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry K. Kvols. The network helps show where Larry K. Kvols may publish in the future.
Co-authorship network of co-authors of Larry K. Kvols
This figure shows the co-authorship network connecting the top 25 collaborators of Larry K. Kvols.
A scholar is included among the top collaborators of Larry K. Kvols based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Larry K. Kvols. Larry K. Kvols is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Kvols, Larry K., Bertram Wiedenmann, Kjell Öberg, et al.. (2010). Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR. Neuroendocrinology. 92(1). 42–43.5 indexed citations
6.
Yao, James C., Catherine Lombard‐Bohas, Éric Baudin, et al.. (2009). Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial. Journal of Clinical Oncology. 28(1). 69–76.487 indexed citations breakdown →
Valkema, Roelf, François Jamar, Stanislas Pauwels, et al.. (2003). Phase 1 study of peptide receptor radionuclide therapy (PRRT) with [Y-90-DOTA,Tyr(3)]octreotide in patients with somatostatin receptor positive tumors. Cancer Biotherapy and Radiopharmaceuticals. 18(2). 295–295.7 indexed citations
Valkema, Roelf, François Jamar, Stanislas Pauwels, et al.. (2001). Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study. European Journal of Nuclear Medicine and Molecular Imaging. 28(8). 1025–1025.10 indexed citations
Knott‐Craig, Christopher J., Hartzell V. Schaff, Charles J. Mullany, et al.. (1992). Carcinoid disease of the heart. Surgical management of ten patients.. PubMed. 104(2). 475–81.34 indexed citations
Powis, Garth, et al.. (1986). Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials.. PubMed. 70(3). 359–62.11 indexed citations
19.
Eagan, Robert T., Stephen Frytak, Edward T. Creagan, et al.. (1979). Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 63(9-10). 1589–91.18 indexed citations
20.
Edmonson, J H, Thomas R. Fleming, David G. Decker, et al.. (1979). Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease.. PubMed. 63(2). 241–7.84 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.